"GSK's Mo-Rez treatment has shown significant efficacy, shrinking or eliminating tumors in 62% of patients with ovarian cancer and 67% of those with endometrial cancer."
"The treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates."
"GSK has gained recognition for its work on superbugs, becoming one of only three major pharmaceutical companies investing in anti-microbial research."
"Despite being a vaccine specialist, GSK was slow to engage during the pandemic, while AstraZeneca produced one of the first Covid-19 vaccines."
GSK has reported positive early-stage trial results for its cancer treatment Mo-Rez, which shrank or eliminated tumors in 62% of ovarian cancer patients and 67% of endometrial cancer patients. The company, based in London, has been recognized for its efforts against superbugs but has faced commercial challenges from AstraZeneca. GSK acquired Mo-Rez from Hansoh Pharma and has conducted trials with 224 patients globally. The results support moving to late-stage trials, with five studies planned, addressing the need for new therapies in gynaecological cancers.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]